Back
  1. Home
  3. Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. - 2019
Download
Article (Scientific journals)
Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins.
D'Haens, Geert; Kelly, Orlaith; Battat, Robert et al.
2019 • In Gastroenterology
Peer Reviewed verified by ORBi
Permalink
https://hdl.handle.net/2268/247539
DOI
10.1053/j.gastro.2019.10.034
PubMed
31711925
 

Files (1)Send toDetailsStatisticsBibliographySimilar publications

Files

Full Text
7_Development and validation of test to monitor endoscopic... serum markers of mucosal healing in Crohn_Gastroenterology_PrePA.pdf
Author preprint (940.43 kB)
Download

Copyright (c) 2019 AGA Institute. Published by Elsevier Inc. All rights reserved. Copyright © 2020 Elsevier B.V. or its licensors or contributors. ScienceDirect ® is a registered trademark of Elsevier B.V. ScienceDirect ® is a registered trademark of Elsevier B.V.

All documents in ORBi are protected by a user license.

Send to


Details


Keywords :
IBD; Monitor; Resolution; Response to Treatment
Abstract :
[en] BACKGROUND & AIMS: Noninvasive tests to measure endoscopic activity in patients with Crohn's disease (CD) have limitations. We aimed to develop a test to identify patients in remission, based on endoscopic analysis, and monitor CD activity based on serum levels of proteins. METHODS: We developed a test to measure 13 proteins in blood (ANG1, ANG2, CRP, SAA1, IL7, EMMPRIN, MMP1, MMP2, MMP3, MMP9, TGFA, CEACAM1, and VCAM1), called the endoscopic healing index [EHI], using samples from 278 patients with CD from a multinational training cohort. We validated the test using 2 independent cohorts of patients with CD: 116 biologic-naive patients with early-stage CD (validation cohort 1) and 195 biologic-exposed patients with chronic CD (validation cohort 2). The ability of the test to identify patients with active disease vs patients in remission (defined as a simple endoscopic score for CD of
Disciplines :
Gastroenterology & hepatology
Author, co-author :
D'Haens, Geert
Kelly, Orlaith
Battat, Robert
Silverberg, Mark S.
Laharie, David
Louis, Edouard  ;  Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Savarino, Edoardo
Bodini, Giorgia
Yarur, Andres
Boland, Brigid S.
Afif, Waqqas
Li, Xiao-Jun
Hale, Michael
Ho, Jessica
Kondragunta, Venkateswarlu
Huang, Benjamin
Kuy, Crystal
Okada, Lauren
Hester, Kelly D.
Bray, Kurtis R.
Mimms, Larry
Jain, Anjali
Singh, Siddharth
Collins, Angelina
Valasek, Mark A.
Sandborn, William J.
Vermeire, Severine
Dulai, Parambir S.
Language :
English
Title :
Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins.
Publication date :
2019
Journal title :
Gastroenterology
ISSN :
0016-5085
eISSN :
1528-0012
Publisher :
Elsevier
Peer reviewed :
Peer Reviewed verified by ORBi
Additional URL :
https://www.sciencedirect.com/science/article/pii/S0016508519415254?via%3Dihub
Commentary :
Copyright (c) 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.
Available on ORBi :
since 19 May 2020

Statistics

Number of views
265 (3 by ULiège)
Number of downloads
135 (3 by ULiège)
More statistics
Scopus citations®
 
89
Scopus citations®
without self-citations
68
OpenAlex citations
 
88

Bibliography

  • Peyrin-Biroulet, L., Loftus, E.V. Jr., Colombel, J.F., et al. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 105 (2010), 289–297.
  • Baert, F., Moortgat, L., Van Assche, G., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 138 (2010), 463–468.
  • Froslie, K.F., Jahnsen, J., Moum, B.A., et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133 (2007), 412–422.
  • af Björkesten, C.G., Nieminen, U., Sipponen, T., et al. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol 48 (2013), 543–551.
  • Shah, S.C., Colombel, J.F., Sands, B.E., et al. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease. Aliment Pharmacol Ther 43 (2016), 317–333.
  • Peyrin-Biroulet, L., Sandborn, W., Sands, B.E., et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110 (2015), 1324–1338.
  • Bouguen, G., Levesque, B.G., Feagan, B.G., et al. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol 13 (2015), 1042–1050.
  • Bouguen, G., Levesque, B.G., Pola, S., et al. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease. Clin Gastroenterol Hepatol 12 (2014), 978–985.
  • Buisson, A., Gonzalez, F., Poullenot, F., et al. Comparative acceptability and perceived clinical utility of monitoring tools: a nationwide survey of patients with inflammatory bowel disease. Inflamm Bowel Dis 23 (2017), 1425–1433.
  • Limketkai, B.N., Singh, S., Jairath, V., et al. US practice patterns and impact of monitoring for mucosal inflammation after biologic initiation in inflammatory bowel disease. Inflamm Bowel Dis 25 (2019), 1828–1837.
  • Colombel, J.F., Panaccione, R., Bossuyt, P., et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 390:10114 (2018), 2779–2789.
  • Lin, J.F., Chen, J.M., Zuo, J.H., et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis 20 (2014), 1407–1415.
  • Mosli, M.H., Zou, G., Garg, S.K., et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol 110 (2015), 802–819.
  • van Deen, W.K., van Oijen, M.G., Myers, K.D., et al. A nationwide 2010–2012 analysis of U.S. health care utilization in inflammatory bowel diseases. Inflamm Bowel Dis 20 (2014), 1747–1753.
  • Pepe, M.S., Feng, Z., Janes, H., et al. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100 (2008), 1432–1438.
  • Bossuyt, P.M., Reitsma, J.B., Bruns, D.E., et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ, 351, 2015, h5527.
  • Louis, E., Mary, J.Y., Vernier-Massouille, G., et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142 (2012), 63–70.
  • D'Haens, G., Vermeire, S., Lambrecht, G., et al. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn's disease. Gastroenterology 154 (2018), 1343–1351.
  • Dulai, P.S., Levesque, B.G., Feagan, B.G., et al. Assessment of mucosal healing in inflammatory bowel disease: review. Gastrointest Endosc 82 (2015), 246–255.
  • Daperno, M., D'Haens, G., Van Assche, G., et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 60 (2004), 505–512.
  • Mary, J.Y., Modigliani, R., Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 30 (1989), 983–989.
  • Padoan, A., D'Inca, R., Scapellato, M.L., et al. Improving IBD diagnosis and monitoring by understanding preanalytical, analytical and biological fecal calprotectin variability. Clin Chem Lab Med 56 (2018), 1926–1935.
  • DeLong, E.R., DeLong, D.M., Clarke-Pearson, D.L., Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44 (1988), 837–845.
  • Simel, D.L., Samsa, G.P., Matchar, D.B., Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol 44 (1991), 763–770.
  • Cohen, J., Statistical power analysis for the behavioral sciences. 2nd ed., 1988, Lawrence Erlbaum, Mahwah, NJ.
  • Heida, A., Knol, M., Kobold, A.M., et al. Agreement between home-based measurement of stool calprotectin and ELISA results for monitoring inflammatory bowel disease activity. Clin Gastroenterol Hepatol 15 (2017), 1742–1749.
  • Yarur, A.J., Quintero, M.A., Jain, A., et al. Serum amyloid A as a surrogate marker for mucosal and histologic inflammation in patients with Crohn's disease. Inflamm Bowel Dis 23 (2017), 158–164.
  • de Bruyn, J.R., van den Brink, G.R., Steenkamer, J., et al. Fibrostenotic phenotype of myofibroblasts in Crohn's disease is dependent on tissue stiffness and reversed by LOX inhibition. J Crohns Colitis 12 (2018), 849–859.
  • Baugh, M.D., Perry, M.J., Hollander, A.P., et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 117 (1999), 814–822.
  • Faubion, W.A. Jr., Fletcher, J.G., O'Byrne, S., et al. EMerging BiomARKers in inflammatory bowel disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging. Am J Gastroenterol 108 (2013), 1891–1900.
  • Schreiber, S., Siegel, C.A., Friedenberg, K.A., et al. A phase 2, randomized, placebo-controlled study evaluating matrix metalloproteinase-9 inhibitor, andecaliximab, in patients with moderately to severely active Crohn's disease. J Crohns Colitis 12 (2018), 1014–1020.
  • Kumar, D., Vetrivel, U., Parameswaran, S., et al. Structural insights on druggable hotspots in CD147: a bull's eye view. Life Sci 224 (2019), 76–87.
  • Till, A., Rosenstiel, P., Brautigam, K., et al. A role for membrane-bound CD147 in NOD2-mediated recognition of bacterial cytoinvasion. J Cell Sci 121 (2008), 487–495.
  • Zaiss, D.M.W., Gause, W.C., Osborne, L.C., et al. Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair. Immunity 42 (2015), 216–226.
  • Algaba, A., Linares, P.M., Encarnacion Fernandez-Contreras, M., et al. The effects of infliximab or adalimumab on vascular endothelial growth factor and angiopoietin 1 angiogenic factor levels in inflammatory bowel disease: serial observations in 37 patients. Inflamm Bowel Dis 20 (2014), 695–702.
  • Linares, P.M., Chaparro, M., Gisbert, J.P., Angiopoietins in inflammation and their implication in the development of inflammatory bowel disease. A review. J Crohns Colitis 8 (2014), 183–190.
  • Martin, C.E., Spasova, D.S., Frimpong-Boateng, K., et al. Interleukin-7 availability is maintained by a hematopoietic cytokine sink comprising innate lymphoid cells and T cells. Immunity 47 (2017), 171–182.
  • Zundler, S., Fischer, A., Schillinger, D., et al. The α4β1 homing pathway is essential for ileal homing of Crohn's disease effector T cells in vivo. Inflamm Bowel Dis 23 (2017), 379–391.
  • Kalla, R., Kennedy, N.A., Ventham, N.T., et al. Serum calprotectin: a novel diagnostic and prognostic marker in inflammatory bowel diseases. Am J Gastroenterol 111 (2016), 1796–1805.
  • Gecse, K.B., Brandse, J.F., van Wilpe, S., et al. Impact of disease location on fecal calprotectin levels in Crohn's disease. Scand J Gastroenterol 50 (2015), 841–847.
  • Stevens, T., D'Haens, G.R., Buskens, C.J., et al. P150. Low diagnostic accuracy of faecal calprotectin to predict mucosal inflammation in Crohn's disease patients with active perianal fistulas. Abstract presented at: European Crohn's and Colitis Organization Congress, 2018 Vienna, Austria.
  • Whitehead, S.J., French, J., Brookes, M.J., et al. Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits. Ann Clin Biochem 50 (2013), 53–61.
  • Oyaert, M., Boel, A., Jacobs, J., et al. Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease. Clin Chem Lab Med 55 (2017), 1564–1573.
  • Rodriguez, A., Yokomizo, L., Christofferson, M., et al. Correlation of rapid point-of-care vs send-out fecal calprotectin monitoring in pediatric inflammatory bowel disease. World J Gastrointest Pharmacol Ther 8 (2017), 127–130.
  • Hejl, J., Theede, K., Mollgren, B., et al. Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis. Pract Lab Med 10 (2018), 10–14.
  • Whitehead, S.J., Ford, C., Gama, R.M., et al. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12. J Clin Pathol 70 (2017), 1049–1056.
  • Jang, H.W., Kim, H.S., Park, S.J., et al. Accuracy of three different fecal calprotectin tests in the diagnosis of inflammatory bowel disease. Intest Res 14 (2016), 305–313.
  • Wright, E.K., Kamm, M.A., De Cruz, P., et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. Gastroenterology 148 (2015), 938–947.

Similar publications


Contact ORBi